Feb 11, 2006
According to a report from free email newsletter FierceBiotech, a federal advisory panel has told the US Food & Drug Adminstration (FDA) that it should apply its toughest warning label on drugs for attention deficit hyperactivity disorder (ADHD), such as Ritalin. According to Fierce, the recommendation comes as a surprise to the FDA, which usually follows its advisory panels’ advice but is not legally required to do so. At issue are reports that these drugs may have an increased link to heart disease risk.
You can subscribe for free to FierceBiotech for daily updates of bio and pharma news, by filling in a simple form on the Sciencebase site